1. Home
  2. PRCH vs ENGN Comparison

PRCH vs ENGN Comparison

Compare PRCH & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PRCH

Porch Group Inc.

HOLD

Current Price

$6.97

Market Cap

753.7M

Sector

Technology

ML Signal

HOLD

Logo enGene Holdings Inc.

ENGN

enGene Holdings Inc.

HOLD

Current Price

$7.68

Market Cap

647.1M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRCH
ENGN
Founded
2012
1999
Country
United States
Canada
Employees
N/A
82
Industry
Computer Software: Prepackaged Software
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
753.7M
647.1M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
PRCH
ENGN
Price
$6.97
$7.68
Analyst Decision
Strong Buy
Buy
Analyst Count
8
6
Target Price
$18.00
$21.08
AVG Volume (30 Days)
1.1M
239.1K
Earning Date
05-05-2026
03-09-2026
Dividend Yield
N/A
N/A
EPS Growth
90.91
N/A
EPS
N/A
N/A
Revenue
$482,414,000.00
N/A
Revenue This Year
$3.89
N/A
Revenue Next Year
$16.80
N/A
P/E Ratio
N/A
N/A
Revenue Growth
10.18
N/A
52 Week Low
$4.65
$2.66
52 Week High
$19.44
$12.25

Technical Indicators

Market Signals
Indicator
PRCH
ENGN
Relative Strength Index (RSI) 43.97 53.24
Support Level $6.54 $6.04
Resistance Level $8.29 $8.14
Average True Range (ATR) 0.42 0.51
MACD -0.01 0.18
Stochastic Oscillator 31.52 97.02

Price Performance

Historical Comparison
PRCH
ENGN

About PRCH Porch Group Inc.

Porch Group Inc is a vertical software company reinventing the home services and insurance industries. It has four reportable segments: Insurance Services, Software & Data, Consumer Services, and Corporate. The majority of revenue is from the Insurance segment. The Insurance Services segment manages and operates the Reciprocal, providing services related, but not limited, to underwriting, policy renewal, risk management, insurance portfolio management, financial management, and setting investment guidelines in exchange for commissions and fees.

About ENGN enGene Holdings Inc.

enGene Holdings Inc is a clinical-stage biotechnology company mainstreaming genetic medicine through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs, beginning with non-muscle invasive bladder cancer (NMIBC). The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.

Share on Social Networks: